KPIs & Operating Metrics(New)
Growth Metrics

Abbott Laboratories (ABT) Free Cash Flow (2016 - 2026)

Abbott Laboratories' Free Cash Flow history spans 18 years, with the latest figure at $916.0 million for Q1 2026.

  • On a quarterly basis, Free Cash Flow fell 1.82% to $916.0 million in Q1 2026 year-over-year; TTM through Mar 2026 was $7.4 billion, a 10.83% increase, with the full-year FY2025 number at $7.4 billion, up 16.44% from a year prior.
  • Free Cash Flow hit $916.0 million in Q1 2026 for Abbott Laboratories, down from $2.6 billion in the prior quarter.
  • Over the last five years, Free Cash Flow for ABT hit a ceiling of $2.6 billion in Q4 2025 and a floor of $627.0 million in Q1 2024.
  • Historically, Free Cash Flow has averaged $1.6 billion across 5 years, with a median of $1.7 billion in 2022.
  • Biggest five-year swings in Free Cash Flow: crashed 65.73% in 2023 and later soared 105.03% in 2024.
  • Tracing ABT's Free Cash Flow over 5 years: stood at $1.7 billion in 2022, then soared by 33.04% to $2.3 billion in 2023, then decreased by 5.91% to $2.1 billion in 2024, then increased by 22.25% to $2.6 billion in 2025, then tumbled by 65.12% to $916.0 million in 2026.
  • Business Quant data shows Free Cash Flow for ABT at $916.0 million in Q1 2026, $2.6 billion in Q4 2025, and $2.3 billion in Q3 2025.